Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia

Comite d'Evaluation et de Diffusion des Innovations Technologiques
Record ID 32001000095
French
Authors' objectives:

This report aims to estimate the value of transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia (BPH) in terms of efficacy, safety, and economic considerations.

Authors' results and conclusions: he literature review indicates TUMT is a virtually bloodless operation that could be performed on an outpatient basis under local anesthesia or intravenous sedation. Studies have shown that there is a placebo effect after sham treatment which, although minimal and certainly less than the effect of TUMT treatment, is essentially significant for subjective parameters. A significant improvement is observed after low-energy TUMT, essentially in the subjective parameters. After high-energy TUMT, a significant improvement is observed in both objective and subjective parameters, but the improvement is generally smaller than that observed after transurethral resection of the prostate (TURP). Thirty-minute high-energy TUMT cannot be adequately assessed from the data currently available. Morbidity levels are significantly lower after TUMT than after TURP, particularly in terms of a lack of major complications and preservation of sexual function. However, adverse effects increase with high-energy devices; lengthy postoperative catheterization period and higher rates of urinary tract infections (UTI) and urinary retention were observed compared to TURP. Moreover, no significant change in prostate volume was achieved by TUMT, and the mean reoperation frequency was considerably higher than for TURP. It has to be noted that an FDA Public Health Notification was published in October 2000 about the potential for serious thermal injury and related complications associated with the use of microwave energy to treat BPH.
Authors' recomendations: In light of the literature review, there are uncertainties concerning the indications for TUMT, especially about the clinical baseline parameters capable of predicting a good response to treatment. However, TUMT appears to be attractive for patients with a medical treatment failure or with contraindications for TURP. In this context, results are required from clinical studies with the new 30-minute high-energy TUMT protocol to provide evidence for the safety and efficacy of the procedure, particularly in terms of long-term outcome and identification of predictive baseline clinical parameters.
Authors' methods: Review
Details
Project Status: Completed
URL for project: http://cedit.aphp.fr/
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
MeSH Terms
  • Costs and Cost Analysis
  • Hyperthermia, Induced
  • Prostatic Diseases
  • Prostatic Hyperplasia
Contact
Organisation Name: Cellule Innovation of the AP-HP
Copyright: Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.